RDHL 8.79 Redhill Biopharma Ltd $RDHL Hit a 52 week low of

New Post Public Reply Private Reply Replies (0) Message Board

Nov 10, 2014 at 10:50 PM

RDHL 8.79 Redhill Biopharma Ltd $RDHL Hit a 52 week low of 8.21 Closing the day 11/10/14 at 8.79 -0.50 -5.38% With a day low of 8.21 and a total volume of 29,705.

RDHL Recent Posts: http://investorshangout.com/Redhill-Biopharma...DHL-89488/

RDHL Redhill Biopharma Ltd Recent Headline News

Redhill Biopharma's (RDHL) CEO Dror Ben Asher on Q3 2014 Results - Earnings Call Transcript
SA Transcripts - at Seeking Alpha - Mon Nov 10, 2:01PM CST

RDHL: 8.79 (-0.50)

FDA tags RedHill's RHB-105 a QIDP
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 11:02AM CST

RDHL: 8.79 (-0.50)

Redhill beats by $0.44
Seeking Alpha - at Seeking Alpha - Mon Nov 10, 7:11AM CST

RDHL: 8.79 (-0.50)

FDA Grants QIDP Fast-Track Designation to RedHill Biopharma's Phase III H. pylori Drug RHB-105
GlobeNewswire - Mon Nov 10, 6:28AM CST
-- Under the FDA's Generating Antibiotic Incentives Now (GAIN) Act, the Qualified Infectious Disease Product (QIDP) designation allows for additional five years of market exclusivity in addition to existing exclusivity, Fast-Track status (an expedited development pathway) and Priority Review status (shortened review time for marketing applications)
RDHL: 8.79 (-0.50)

RedHill Biopharma Reports Results for the Third Quarter of 2014
GlobeNewswire - Mon Nov 10, 5:30AM CST
-- A strong cash position of approximately $29 million at the end of the third quarter of 2014, enabling the Company to continue to execute its R&D programs including the three ongoing Phase III studies in gastrointestinal indications: RHB-104 for Crohn's disease, RHB-105 for H. pylori infection and RHB-102 for acute gastroenteritis and gastritis
RDHL: 8.79 (-0.50)

RedHill Bio reports November 10
Seeking Alpha - at Seeking Alpha - Tue Oct 28, 9:39AM CDT

RDHL: 8.79 (-0.50)

RedHill Biopharma to Host Third Quarter 2014 Financial Results Conference Call on November 10, 2014
GlobeNewswire - Tue Oct 28, 6:15AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that it will report financial results for the third quarter of 2014 on Monday, November 10, 2014.
RDHL: 8.79 (-0.50)

RedHill Biopharma to Present at the 20th Annual BIO-Europe International Partnering Conference
GlobeNewswire - Wed Oct 22, 8:44AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"

, a Canadian drug delivery company focused on oral drug delivery, that they have submitted a Marketing Authorization Application ("MAA"

to the German Federal Institute for Drugs and Medical Devices ("BfArM"

seeking European marketing approval of RHB-103, an oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT. The brand name RIZAPORT for RHB-103 was also conditionally approved by the U.S. Food and Drug Administration ("FDA"

as part of the New Drug Application ("NDA"

review process in the U.S., subject to a Complete Response Letter ("CRL"

received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 8.79 (-0.50), IGX.VN: 0.400 (+0.010)

IntelGenx and RedHill Biopharma Submit European Marketing Authorization Application for Migraine Drug RIZAPORT(R)
GlobeNewswire - Wed Oct 01, 9:21AM CDT
IntelGenx Corp. (TSX-V:IGX) (OTCQX:IGXT) ("IntelGenx"

, a Canadian drug delivery company focused on oral drug delivery, today announced, together with RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) ("RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, that they have submitted a Marketing Authorization Application ("MAA"

to the German Federal Institute for Drugs and Medical Devices ("BfArM"

seeking European marketing approval of their oral thin film formulation of rizatriptan for acute migraines, under the brand name RIZAPORT(R). The brand name RIZAPORT(R) was also conditionally approved by the U.S. Food and Drug Administration ("FDA"

as part of the New Drug Application ("NDA"

review process in the U.S., subject to a Complete Response Letter ("CRL"

received from the FDA in February 2014 and currently under discussions with the FDA.
RDHL: 8.79 (-0.50), IGX.VN: 0.400 (+0.010)

RedHill Biopharma to Present at the 14th Annual Biotech In Europe Forum for Global Partnering & Investment
GlobeNewswire - Tue Sep 16, 6:13AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Adi Frish, RedHill's Senior VP Business Development and Licensing, will be presenting at the 7 Annual BioPharm America International Partnering Conference, on Tuesday, September 23, 2014, at 2:45 p.m. EDT, in the Suffolk room of the Boston Marriott Copley Placein Boston, Massachusetts.
RDHL: 8.79 (-0.50)

Global Migraine Drug Forecast and Market Analysis to 2023 - A Potential $3.7 Billion Market
M2 - Thu Sep 11, 4:07AM CDT
Research and Markets (http://www.researchandmarkets.com/research/5qmmg2/pharmapoint) has announced the addition of the "PharmaPoint: Migraine - Global Drug Forecast and Market Analysis to 2023" report to their offering. The migraine market is saturated with generic drugs, and the remaining branded products already on the market are expected to lose exclusivity during the next few years, with the exception of Botox for chronic migraine, which is expected to maintain its leading position in terms of sales. However, reformulations of mature products as well as new classes of therapies are anticipated to launch during the forecast period and these will contribute to the market growth. By 2023, the migraine market will grow to $3.7 billion at a compound annual growth rate (CAGR) of 3.6%, with the US continuing to dominate the market as a result of higher drug prices and a large migraine population. Some of the new treatments are expected to target the key unmet needs but opportunities will remain for further treatment choices especially drugs that will offer an improved safety and side-effects profile. Key Findings - The main driver of the expansion of the migraine market will be the continuous use of Botox for chronic migraine. The introduction of reformulations of mature products as well as new classes of therapies will further increase the market size. - The biggest barrier for the introduction of new therapies will be patent expirations of the majority of the drugs marketed for migraine, which have resulted in an increase of generics, and which may negatively impact revenue from branded drugs that are expected to launch in the forecast period. - The concerns of reducing healthcare costs as part of government austerity measures, particularly in Europe, which will impede market growth. To ensure reimbursement companies will have to work closely together with payers and price their drugs competitively. Key Topics Covered: 1 Tables & Figures 2 Introduction 3 Disease Overview 4 Epidemiology 5 Disease Management 6 Competitive Assessment 7 Opportunity and Unmet Need 8 Pipeline Assessment 9 Current and Future Players 10 Market Outlook 11 Appendix Companies Mentioned - GlaxoSmithKline - AstraZeneca - Merck - Vernalis - Almirall - Pfizer - Zogenix - NuPathe - Allergan - RedHill Biopharma - OptiNose - CoLucid Pharmaceuticals - SUDA - Revance Therapeutics - NeurAxon For more information visit http://www.researchandmarkets.com/research/5q...harmapoint
AGN: 195.24 (-0.76), RDHL: 8.79 (-0.50), MRK: 58.81 (-0.53), RVNC: 20.30 (+0.51), GSK: 45.16 (+0.25)

RedHill Biopharma to Present at the Rodman & Renshaw 16th Annual Global Investment Conference
GlobeNewswire - Thu Sep 04, 11:30AM CDT
RedHill Biopharma Ltd. (Nasdaq:RDHL) (TASE:RDHL) (the "Company" or "RedHill"

, an Israeli biopharmaceutical company focused on late clinical-stage drugs for inflammatory and gastrointestinal diseases, including gastrointestinal cancers, today announced that Dror Ben-Asher, RedHill's Chief Executive Officer, will be presenting at the Rodman & Renshaw 16 Annual Global Investment Conference, on Wednesday, September 10, 2014, at 1:40 p.m. EDT, in the Holmes II Salon of the New York Palace Hotel in New York City.
RDHL: 8.79 (-0.50)

RedHill Biopharma Initiates Phase III Study of RHB-102 for Gastroenteritis
GlobeNewswire - Wed Sep 03, 6:00AM CDT
-- The randomized, double-blind, placebo-controlled, parallel group Phase III study with RHB-102 (the GUARD study) will enroll 320 acute gastroenteritis patients in the U.S.
RDHL: 8.79 (-0.50)

RedHill Expands ERADICATE Study on RHB-105 for H. pylori - Analyst Blog
Zacks Equity Research - Zacks Investment Research - Thu Aug 28, 5:40PM CDT
RedHill Biopharma Ltd. (RDHL) recently provided an update on the ongoing phase III study ERADICATE Hp, on pipeline candidate RHB-105 for Helicobacter pylori infection (H. pylori).
AGN: 195.24 (-0.76), RDHL: 8.79 (-0.50), GILD: 107.02 (+0.57), RGDO: 0.88 (-0.05)

RedHill Biopharma Provides Update on Expansion of Ongoing RHB-105 Phase III Study, Targeting Broadened H. pylori Indication Authorized by FDA
GlobeNewswire - Wed Aug 27, 7:25AM CDT
-- In order to enhance statistical powering and expedite recruitment, RedHill has increased the number of subjects and clinical sites, respectively, in the ongoing RHB-105 Phase III ERADICATE Hp study, with top-line data currently expected in the first half of 2015
RDHL: 8.79 (-0.50)

RedHill Biopharma Acquires Option for Phase II Pancreatic Cancer Drug RP101
GlobeNewswire - Wed Aug 13, 9:15AM CDT
-- Potentially expanding its gastrointestinal-focused pipeline, RedHill has secured an option to acquire RP101 from Dresden-based RESprotect GmbH, a spin-off from the Fraunhofer-Society
RDHL: 8.79 (-0.50)